Your session is about to expire
← Back to Search
Cabozantinib + Pembrolizumab for Metastatic Pancreatic Cancer
Study Summary
This trial will test if cabozantinib and pembrolizumab can treat pancreatic cancer that has spread.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a serious heart condition.I cannot swallow pills.My pancreatic cancer has worsened or I couldn't tolerate previous treatments.I have an autoimmune disease or am on long-term steroids.My high blood pressure is not under control.I have been diagnosed with pancreatic cancer.My organs are functioning well.I have not had any cancer treatment or experimental drugs in the last 4 weeks.I haven't had chemotherapy or targeted cancer treatments in the last 28 days.I had palliative radiation within 2 weeks or any radiation within 4 weeks before starting the study.
- Group 1: Cabozantinib and pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the primary indication that doctors prescribe Cabozantinib for?
"Cabozantinib is frequently used to treat patients with unresectable melanoma. It can also help those with microsatellite instability high, a high risk of recurrence, and disease."
Might I be eligible to enroll in this experiment?
"Eligible patients must have cancer of the pancreas, be between 18 and 99 years old, and have evidence of progression or intolerance to previous standard of care pancreatic cancer systemic or locoregional therapies. Additionally, all potential participants must have adequate organ function."
Are we currently looking for volunteers for this research project?
"Yes, as of February 26th, 2022 this clinical trial is still looking for eligible patients. This research was initially posted on January 4th, and the most recent changes were made to the study's information on that date. So far, 1 location is set to enroll 21 individuals in total."
Are there any other instances where Cabozantinib has been trialed as a treatment?
"As of now, there are 1108 clinical trials underway that involve Cabozantinib. Out of those active studies, 135 are in Phase 3. The largest amount of research for Cabozantinib is taking place in Houston, Texas; however, 43127 different locations are running studies concerning this treatment."
Are people aged 45 or older welcome in this clinical trial?
"This trial includes patients that are over 18 and younger than 99."
What is the total number of people who can participate in this clinical trial?
"Yes, the most recent update on clinicaltrials.gov indicates that this study is looking for 21 more participants. The trial was first posted on January 4th, 2022 and updated February 26th, 2022. Currently, 1 location is recruiting patients for the study."
Are there any life-threatening risks associated with Cabozantinib?
"Since this is a Phase 2 trial, cabozantinib's safety has been supported to some degree but there is no data yet confirming its efficacy. Consequently, it received a score of 2."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger